title: Circulating enterolactone and risk of endometrial cancer.
abstract: It has been suggested that phytoestrogens protect against hormone-dependent cancers. Lignans are the main class of phytoestrogens in Western diets. We conducted a prospective study of endometrial cancer and circulating levels of the main human lignan, enterolactone. The design was a case-control study nested within 3 prospective cohort studies, in New York, Sweden and Italy. Serum or plasma samples had been collected at enrollment and stored at -80 degrees C. A total of 153 cases, diagnosed a median of 5.3 years after blood donation, and 271 matched controls were included. No difference in circulating enterolactone was observed between cases (median, 19.2 nmol/L) and controls (18.5 nmol/L). Adjusting for body mass index, the odds ratio for the top tertile of enterolactone, as compared to the lowest was 1.2 (95% CI, 0.7-2.0; p for trend = 0.53). Lack of association was observed in both pre- and postmenopausal women. No correlation was observed between enterolactone and circulating estrogens or SHBG in healthy postmenopausal women. These results do not support a protective role of circulating lignans, in the range of levels observed, against endometrial cancer.
authors.affiliation: Department of Environmental Medicine, New York University School of Medicine, New York, NY 10016-3240, USA. anne.jacquotte@med.nyu.edu
authors.forename: Anne
authors.initials: A
authors.lastname: Zeleniuch-Jacquotte
authors.forename: Eva
authors.initials: E
authors.lastname: Lundin
authors.forename: Andrea
authors.initials: A
authors.lastname: Micheli
authors.forename: Karen L
authors.initials: KL
authors.lastname: Koenig
authors.forename: Per
authors.initials: P
authors.lastname: Lenner
authors.forename: Paola
authors.initials: P
authors.lastname: Muti
authors.forename: Roy E
authors.initials: RE
authors.lastname: Shore
authors.forename: Ingegerd
authors.initials: I
authors.lastname: Johansson
authors.forename: Vittorio
authors.initials: V
authors.lastname: Krogh
authors.forename: Annekatrin
authors.initials: A
authors.lastname: Lukanova
authors.forename: Pär
authors.initials: P
authors.lastname: Stattin
authors.forename: Yelena
authors.initials: Y
authors.lastname: Afanasyeva
authors.forename: Sabina
authors.initials: S
authors.lastname: Rinaldi
authors.forename: Alan A
authors.initials: AA
authors.lastname: Arslan
authors.forename: Rudolf
authors.initials: R
authors.lastname: Kaaks
authors.forename: Franco
authors.initials: F
authors.lastname: Berrino
authors.forename: Göran
authors.initials: G
authors.lastname: Hallmans
authors.forename: Paolo
authors.initials: P
authors.lastname: Toniolo
authors.forename: Herman
authors.initials: H
authors.lastname: Adlercreutz
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000097:blood; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D016889:Endometrial Neoplasms / Q000097:blood*; D005260:Female; D006801:Humans; D007558:Italy; D017705:Lignans / Q000097:blood*; D008875:Middle Aged; D009518:New York; D016017:Odds Ratio; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013548:Sweden
chemical_list: D014408:Biomarkers, Tumor; D017705:Lignans; D015107:4-Butyrolactone; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone